0 154

Cited 48 times in

(11)C-PBR28 binding to translocator protein increases with progression of Alzheimer's disease

Authors
 William C. Kreisl  ;  Chul Hyoung Lyoo  ;  Jeih-San Liow  ;  Monica Wei  ;  Joseph Snow  ;  Emily Page  ;  Kimberly J. Jenko  ;  Cheryl L. Morse  ;  Sami S. Zoghbi  ;  Victor W. Pike  ;  R. Scott Turner 
Citation
 Neurobiology of Aging, Vol.44 : 53-61, 2016 
Journal Title
 Neurobiology of Aging 
ISSN
 0197-4580 
Issue Date
2016
MeSH
Acetamides/metabolism* ; Aged ; Alzheimer Disease/diagnostic imaging* ; Alzheimer Disease/metabolism* ; Biomarkers/metabolism ; Brain/diagnostic imaging* ; Carbon Radioisotopes/metabolism* ; Disease Progression ; Female ; Humans ; Longitudinal Studies ; Magnetic Resonance Imaging ; Male ; Middle Aged ; Neuroimaging ; Positron-Emission Tomography ; Protein Binding ; Pyridines/metabolism* ; Radiopharmaceuticals/metabolism* ; Receptors, GABA/metabolism*
Keywords
Alzheimer's disease ; Neuroinflammation ; PET imaging
Abstract
This longitudinal study sought to determine whether the 18 kDa translocator protein (TSPO), a marker of neuroinflammation, increases over time in Alzheimer's disease. Positron emission tomography imaging with the TSPO radioligand (11)C-PBR28 was performed at baseline and after a median follow-up of 2.7 years in 14 amyloid-positive patients and 8 amyloid-negative controls. Patients had a greater increase in TSPO binding than controls in inferior parietal lobule, precuneus, occipital cortex, hippocampus, entorhinal cortex, and combined middle and inferior temporal cortex. TSPO binding in temporoparietal regions increased from 3.9% to 6.3% per annum in patients, but ranged from -0.5% to 1% per annum in controls. The change in TSPO binding correlated with cognitive worsening on clinical dementia rating scale-sum of boxes and reduced cortical volume. The annual rate of increased TSPO binding in temporoparietal regions was about 5-fold higher in patients with clinical progression (n = 9) compared with those who did not progress (n = 5). TSPO may serve as a biomarker of Alzheimer's progression and response to anti-inflammatory therapies.
Full Text
http://www.sciencedirect.com/science/article/pii/S0197458016300458
DOI
10.1016/j.neurobiolaging.2016.04.011
Appears in Collections:
1. Journal Papers (연구논문) > 1. College of Medicine (의과대학) > Dept. of Neurology (신경과학교실)
Yonsei Authors
류철형(Lyoo, Chul Hyoung)
Export
RIS (EndNote)
XLS (Excel)
XML
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/151811
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse